Biotech Values

[rx_usa]

I believe GSK is beginning to push hard to gain marketshare by discounting as much as 60%. If they push hard enough, it's just a matter of time Arixtra will catch on. Besides, they have the clinical pharmacists on their side. Many of the patients on Lovenox are managed by pharmacists, especially in the HMO setting, and they overwhelmingly favor Arixtra over Lovenox.